Evidence map›Paper›PMID 35020437›Full record

ArticleScience advances2022

Engineered neutrophil-derived exosome-like vesicles for targeted cancer therapy.

Jiahui Zhang, Cheng Ji, Hongbo Zhang, Hui Shi, Fei Mao, Hui Qian, Wenrong Xu, Dongqing Wang, Jianming Pan, Xinjian Fang and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Science advances, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 153 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
153citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

153 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Green nanomedicine for cancer therapy.Chinese medical journal · 2026
    Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review

93 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Jiahui ZhangJiangsu Key Laboratory of Medical Science and Laboratory Medicine, School of Medicine, Jiangsu University, 212013 Zhenjiang, China.ORCID 0000-0002-8163-1298
Cheng JiJiangsu Key Laboratory of Medical Science and Laboratory Medicine, School of Medicine, Jiangsu University, 212013 Zhenjiang, China.ORCID 0000-0002-1117-9208
Hongbo ZhangPharmaceutical Sciences Laboratory, Åbo Akademi University, 20520 Turku, Finland.ORCID 0000-0002-1071-4416
Hui ShiJiangsu Key Laboratory of Medical Science and Laboratory Medicine, School of Medicine, Jiangsu University, 212013 Zhenjiang, China.
Fei MaoJiangsu Key Laboratory of Medical Science and Laboratory Medicine, School of Medicine, Jiangsu University, 212013 Zhenjiang, China.
Hui QianJiangsu Key Laboratory of Medical Science and Laboratory Medicine, School of Medicine, Jiangsu University, 212013 Zhenjiang, China.ORCID 0000-0002-0098-3196
Wenrong XuJiangsu Key Laboratory of Medical Science and Laboratory Medicine, School of Medicine, Jiangsu University, 212013 Zhenjiang, China.
Dongqing WangDepartment of Radiology, Affiliated Hospital of Jiangsu University, Jiangsu University, 212001 Zhenjiang, China.
Jianming PanSchool of Chemistry and Chemical Engineering, Jiangsu University, 212013 Zhenjiang, China.
Xinjian FangDepartment of Oncology, Lianyungang Hospital Affiliated to Jiangsu University, Lianyungang, Jiangsu 222000, China.ORCID 0000-0002-0366-5521
Hélder A SantosDepartment of Biomedical Engineering, University Medical Center Groningen/University of Groningen, W.J. Kolff Institute for Biomedical Engineering and Materials Science, Ant. Deusinglaan 1, 9713 AV Groningen, Netherlands.ORCID 0000-0001-7850-6309
Xu ZhangJiangsu Key Laboratory of Medical Science and Laboratory Medicine, School of Medicine, Jiangsu University, 212013 Zhenjiang, China.ORCID 0000-0003-3492-4618

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neutrophils are the most abundant innate immune cells in human circulation; however, their derived exosomes have been rarely studied for tumor treatment. Here, we reported that exosomes from neutrophils (N-Ex) induce tumor cell apoptosis by delivering cytotoxic proteins and activating caspase signaling pathway. In addition, we decorated N-Ex with superparamagnetic iron oxide nanoparticles (SPIONs) to achieve higher tumor-targeting therapeutic effect. We further fabricated exosome-like nanovesicles from neutrophils (NNVs) at high yield. Compared with liposome-loaded doxorubicin (DOX) and natural NNVs, DOX-loaded NNVs show an improved inhibition of tumor cell proliferation. Moreover, DOX-loaded, SPION-decorated NNVs selectively accumulate at the tumor sites under an external magnetic field, effectively restraining tumor growth and extensively prolonging the survival rate in mice. Overall, a simple and effective method to engineer N-Ex and NNVs at clinical applicable scale was developed, which enables the efficient and safe drug delivery for targeted and combined tumor therapy.

Identifiers

PMID35020437
PMCPMC8754405

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.